

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A transgenic mouse, comprising a transferred recombinant mouse GANP gene encoding and expressing a protein of SEQ ID NO: 2 [[or 4]] or progeny thereof encoding and expressing said protein, wherein said transgenic mouse produces high affinity antibody-producing B cells.

2. **(Previously Presented)** The transgenic mouse according to claim 1, wherein the GANP gene is expressed in B cells of the transgenic mouse, or its progeny.

3-4. **(Canceled)**

5. **(Currently Amended)** A part of a transgenic mouse, comprising a transferred recombinant mouse GANP gene encoding and expressing a protein of SEQ ID NO: 2 [[or 4]], or progeny thereof encoding and expressing said protein, wherein said part of the transgenic mouse produces high affinity antibody-producing B cells.

6. **(Previously Presented)** A method of producing a high affinity antibody, comprising: administering an antigen to the transgenic mouse according to claim 1 or its progeny; waiting for a time sufficient for said mouse to generate antibodies to said antigen; and recovering the antibody from the resultant mouse or progeny.

7-11. **(Cancelled)**

12. **(Currently Amended)** A high affinity-antibody producing cell which is taken from a transgenic mouse, comprising a transferred recombinant mouse GANP gene encoding and expressing a protein comprising SEQ ID NO: 2 [[or 4]], or progeny thereof encoding and expressing said protein, and wherein said transgenic mouse or its progeny has been administered an antigen.

13. (Previously Presented) The method according to claim 6, comprising:
obtaining blood from the mouse after administration of the antigen, separating and purifying antibodies from the blood to recover the antibody.

14. (Previously Presented) The method according to claim 6, wherein the antigen is administered two to three times at intervals of from 7 to 30 days.

15. (Previously Presented) The method according to claim 6, wherein an administration dose of the antigen is from 0.05 mg to 2 mg.

16. (Previously Presented) The method according to claim 6, wherein the route of administration is subcutaneous, dermal, intraperitoneal, intravenous or intramuscular.

17. (Previously Presented) The transgenic mouse according to claim 1, wherein said GANP gene is operably linked to a human IgG enhancer, or its progeny.

18. (Previously Presented) The method according to claim 6, wherein said GANP gene is operably linked to a human IgG enhancer.

19. (Previously Presented) The cell according to claim 12, wherein said GANP gene is operably linked to a human IgG enhancer, or its progeny.